Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
On Feb 1, 2013, we uplifted our long-term recommendation on HSBC Holdings plc ( HBC - Analyst Report ) to ‘Neutral’ from ‘Underperform’ based on the elimination of regulatory pressure related to its foreclosure mess. Yet, we remain skeptical about the huge financial impact of the penalty imposed owing to its involvement in the money laundering scandal.
Why the Upgrade?
In mid-Jan 2013, HSBC announced a foreclosure settlement deal with the Office of the Comptroller of the Currency (OCC) and other U.S. banking regulators. The settlement comes as a huge relief as it will enable the company to move away from the foreclosure mess and also lessen a massive regulatory overhang.
Following the deal announcement, the Zacks Consensus Estimate for 2012 has gone up 2.5% to $4.45 per share. Likewise, the Zacks Consensus Estimate for 2013 has moved north (up 4.3% to $5.05 per share). With the Zacks Consensus Estimates for both 2012 and 2013 going up, the company now has a Zacks Rank #3 (Hold).
Other Positives
HSBC’s restructuring program, started in 2011, remains on track to achieve targeted cost savings of $3.5 billion by the end of this year. The main intention of the initiative is to focus on the fast-growing and profitable markets along with improvement in overall efficiency.
Moreover, amidst an uncertain macro environment, HSBC remains strong with respect to its balance sheet and capital position. Also, continuously improving profitability ratios are a major positive at HSBC.
Other Major Foreign Banks to Consider
Besides HSBC, other foreign banks that are currently performing well include Credit Suisse Group ( CS - Snapshot Report ) , Canadian Imperial Bank of Commerce ( CM - Snapshot Report ) and UBS AG ( UBS - Analyst Report ) . All these companies carry a Zacks Rank #2 (Buy).
Read the full reports :
Snapshot Report on CS
Analyst Report on UBS
Analyst Report on HBC
Snapshot Report on CM